Treatment · United States
Zurzuvae, the first oral postpartum depression treatment, becomes available in the U.S.
The 14-day oral course offers an alternative to the IV-only brexanolone that preceded it.
These are short summaries of research and reporting published elsewhere. We link to the original. Mental Hum does not report these stories.
Mental Hum is owned and operated by Dean Shaban
Biogen and Sage Therapeutics' Zurzuvae (zuranolone) became the first FDA-approved oral medication specifically for postpartum depression when it launched in the U.S. in late 2023. The 14-day, once-daily course is a major practical step forward from brexanolone, which required a 60-hour IV infusion and a certified inpatient setting.
Trial data showed rapid symptom improvement, by Day 15 and as early as Day 3. Open questions remain about cost, insurance coverage, and how the drug fits alongside SSRIs in real-world practice.
Read Biogen's launch release for the dosing and trial details.
Mental Hum is a reading list, not a publisher. The summary above is our own editorial framing; the reporting and analysis live at the source.